Clinical Trials Browser

Blood Protein Disorders, Disease, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders

NCT07095452 2026-04-16

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Phase 2/3 Recruiting

660 enrolled

Plasma cell

Multiple Myeloma

NCT05623020 2026-04-15

MagnetisMM-6

Phase 3 Recruiting

1,116 enrolled

Plasma cell

Multiple Myeloma

NCT07455851 2026-04-15

A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma

Phase 1/2 Recruiting

150 enrolled

Plasma cell

Multiple Myeloma

NCT06615479 2026-04-14

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Phase 3 Recruiting

440 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT07030517 2026-04-14

A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma

Phase 4 Recruiting

75 enrolled

Plasma cell

Multiple Myeloma

NCT07409246 2026-04-14

A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)

Phase 1 Recruiting

127 enrolled

Plasma cell

Multiple Myeloma, Neoplasms

NCT07529782 2026-04-14

Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma

Phase 1 Recruiting

15 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04634552 2026-04-13

MonumenTAL-1

Phase 2 Recruiting

510 enrolled 2 FDA

Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms

NCT05160584 2026-04-13

MoMMent

Recruiting

300 enrolled

Plasma cell

Multiple Myeloma

NCT05201781 2026-04-13

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

Phase 4 Recruiting

295 enrolled

Plasma cell

Multiple Myeloma

NCT05438043 2026-04-13

A Study of Daratumumab

Phase 3 Recruiting

500 enrolled

Plasma cell

Multiple Myeloma

NCT05552222 2026-04-13

MajesTEC-7

Phase 3 Recruiting

1,590 enrolled

Plasma cell

Multiple Myeloma

NCT05652335 2026-04-13

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

Phase 1 Recruiting

180 enrolled

Plasma cell

Amyloidosis, Multiple Myeloma, Recurrence

NCT06285318 2026-04-13

REALiTEC/TAL

Recruiting

900 enrolled

Plasma cell

Multiple Myeloma

NCT06433947 2026-04-13

Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma

Phase 1 Recruiting

130 enrolled

Plasma cell

Multiple Myeloma

NCT06500884 2026-04-13

Talisman

Phase 2 Recruiting

210 enrolled

Plasma cell

Multiple Myeloma

NCT06604715 2026-04-13

A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma

Phase 1 Recruiting

80 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT06669247 2026-04-13

COSTIMM

Phase 1/2 Recruiting

186 enrolled

Plasma cell

Multiple Myeloma

NCT06768489 2026-04-13

A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma

Phase 1 Recruiting

140 enrolled

Plasma cell

Multiple Myeloma

NCT06934044 2026-04-13

A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma

Phase 1 Recruiting

20 enrolled

Plasma cell

Multiple Myeloma

NCT07149857 2026-04-13

CARTITUDE-10

Phase 2 Recruiting

60 enrolled

Plasma cell

Multiple Myeloma

NCT07258511 2026-04-13

TRIlogy-4

Phase 3 Recruiting

400 enrolled

Plasma cell

Multiple Myeloma

NCT07266441 2026-04-13

TRIlogy-3

Phase 2 Recruiting

157 enrolled

Plasma cell

Multiple Myeloma

NCT07523555 2026-04-13

ADAPT-HEM

Phase 1/2 Recruiting

96 enrolled

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Blastic Plasmacytoid Dendritic Cell Neoplasm, Burkitt Lymphoma, Leukemia, Plasma Cell, Multiple Myeloma, Recurrence, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04960579 2026-04-09